Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $18.84 and traded as high as $20.26. Tandem Diabetes Care shares last traded at $20.07, with a volume of 4,396,478 shares trading hands.
Tandem Diabetes Care News Summary
Investors following TNDM have been watching these news items:
- Positive Sentiment: The FDA cleared Tandem Mobi as the first automated insulin delivery system offering both tubed and tubeless wear options, with up to seven days of wear. Tandem expects to launch the tubeless option in 2027, giving the company a new potential growth opportunity. Article: Tandem Mobi Becomes Only Insulin Pump Offering Both Tubed and Tubeless Wear Options
- Positive Sentiment: Health Canada approved expanded use of Tandem’s t:slim X2 insulin pump with Control-IQ+ technology, extending the product’s availability in Canada. Article: Tandem Diabetes Care Receives Health Canada Approvals
- Neutral Sentiment: The tubeless Mobi launch is planned for 2027, so commercial and financial benefits are prospective rather than immediate. Article: Tandem Mobi FDA Clearance
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on TNDM. Canaccord Genuity Group set a $40.00 price target on shares of Tandem Diabetes Care in a research report on Friday, August 7th. Oppenheimer reaffirmed an “outperform” rating on shares of Tandem Diabetes Care in a research note on Friday, August 7th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $26.00 target price (down from $30.00) on shares of Tandem Diabetes Care in a research note on Friday, August 7th. Wells Fargo & Company cut their price objective on Tandem Diabetes Care from $27.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, November 6th. Finally, William Blair began coverage on shares of Tandem Diabetes Care in a research report on Friday, August 21st. They issued an “outperform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $27.18.
Check Out Our Latest Stock Report on Tandem Diabetes Care
Tandem Diabetes Care Trading Up 14.6%
The business has a 50-day simple moving average of $17.40 and a two-hundred day simple moving average of $18.84. The company has a debt-to-equity ratio of 4.47, a current ratio of 3.20 and a quick ratio of 2.65. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of -27.87 and a beta of 1.59.
Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.15. The business had revenue of $283.69 million during the quarter, compared to the consensus estimate of $265.85 million. Tandem Diabetes Care had a negative return on equity of 35.61% and a negative net margin of 4.58%. The company’s quarterly revenue was up 13.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.31) EPS. Equities analysts forecast that Tandem Diabetes Care, Inc. will post -0.61 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, Director Christopher J. Twomey sold 1,700 shares of the business’s stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total value of $32,555.00. Following the completion of the sale, the director directly owned 24,434 shares in the company, valued at $467,911.10. The trade was a 6.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.10% of the company’s stock.
Institutional Trading of Tandem Diabetes Care
A number of institutional investors have recently bought and sold shares of the business. Integrated Wealth Concepts LLC bought a new stake in shares of Tandem Diabetes Care during the 2nd quarter valued at $33,000. Sterling Capital Management LLC grew its stake in shares of Tandem Diabetes Care by 849.0% in the third quarter. Sterling Capital Management LLC now owns 2,325 shares of the medical device company’s stock worth $38,000 after purchasing an additional 2,080 shares during the last quarter. Fulcrum Asset Management LLP grew its position in shares of Tandem Diabetes Care by 1,463.6% in the 3rd quarter. Fulcrum Asset Management LLP now owns 4,378 shares of the medical device company’s stock valued at $73,000 after buying an additional 4,098 shares during the last quarter. Prosperitas Financial LLC bought a new stake in Tandem Diabetes Care in the second quarter valued at approximately $151,000. Finally, Provenance Wealth Advisors LLC acquired a new stake in shares of Tandem Diabetes Care during the third quarter worth $158,000.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care develops and commercializes technology for people who use insulin to manage diabetes. Its products include insulin pumps, infusion sets and related supplies, along with software for viewing and sharing diabetes-management data. The company’s offerings include the t:slim X2 insulin pump and the Tandem Mobi pump, as well as Control-IQ technology, which can automatically adjust insulin delivery based on continuous glucose monitor readings when used with compatible devices. Tandem also provides mobile apps and cloud-based tools to support users and healthcare providers.
Further Reading
- Five stocks we like better than Tandem Diabetes Care
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.
